Diamedica Therapeutics Included In Response To FDA Is Protocol Amendment To Incorporate Reduced Dose For Intravenous Administration Of DM199
Portfolio Pulse from Benzinga Newsdesk
Diamedica Therapeutics has amended its protocol in response to the FDA, incorporating a reduced dose for intravenous administration of DM199. The change was disclosed in an 8K filing.
May 22, 2023 | 9:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Diamedica Therapeutics' stock may be impacted by the FDA's protocol amendment to incorporate a reduced dose for intravenous administration of DM199.
The FDA's protocol amendment directly affects Diamedica Therapeutics' DM199 treatment. While the reduced dose may be seen as a positive step towards ensuring safety and efficacy, it is unclear how this change will impact the stock price in the short term. The relevance is 100 as DMAC is the company mentioned in the article, and the importance is 75 as the news pertains to a key product. The confidence level is set at 80 as the impact on the stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100